Literature DB >> 20484036

Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.

Mabrouka Doghman1, Abeer El Wakil, Bruno Cardinaud, Emilie Thomas, Jinling Wang, Wei Zhao, Maria Helena C Peralta-Del Valle, Bonald C Figueiredo, Gerard P Zambetti, Enzo Lalli.   

Abstract

MicroRNAs (miRNAs) act at the posttranscriptional level to control gene expression in virtually every biological process, including oncogenesis. Here, we report the identification of a set of miRNAs that are differentially regulated in childhood adrenocortical tumors (ACT), including miR-99a and miR-100. Functional analysis of these miRNAs in ACT cell lines showed that they coordinately regulate expression of the insulin-like growth factor-mammalian target of rapamycin (mTOR)-raptor signaling pathway through binding sites in their 3'-untranslated regions. In these cells, the active Ser(2448)-phosphorylated form of mTOR is present only in mitotic cells in association with the mitotic spindle and midbody in the G(2)-M phases of the cell cycle. Pharmacologic inhibition of mTOR signaling by everolimus greatly reduces tumor cell growth in vitro and in vivo. Our results reveal a novel mechanism of regulation of mTOR signaling by miRNAs, and they lay the groundwork for clinical evaluation of drugs inhibiting the mTOR pathway for treatment of adrenocortical cancer. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484036      PMCID: PMC2880211          DOI: 10.1158/0008-5472.CAN-09-3970

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

2.  MicroRNA expression profiles in serous ovarian carcinoma.

Authors:  Eun Ji Nam; Heejei Yoon; Sang Wun Kim; Hoguen Kim; Young Tae Kim; Jae Hoon Kim; Jae Wook Kim; Sunghoon Kim
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

3.  Depletion of type IA regulatory subunit (RIalpha) of protein kinase A (PKA) in mammalian cells and tissues activates mTOR and causes autophagic deficiency.

Authors:  Manos Mavrakis; Jennifer Lippincott-Schwartz; Constantine A Stratakis; Ioannis Bossis
Journal:  Hum Mol Genet       Date:  2006-09-08       Impact factor: 6.150

4.  Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF.

Authors:  Markus Guba; Maksim Yezhelyev; Martin E Eichhorn; Gerald Schmid; Ivan Ischenko; Armine Papyan; Christian Graeb; Hendrik Seeliger; Edward K Geissler; Karl-Walter Jauch; Christiane J Bruns
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

5.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

6.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Aaron C Spalding; Joanne H Heaton; Rork Kuick; Alex C Kim; Dafydd G Thomas; Thomas J Giordano; Edgar Ben-Josef; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

7.  Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication.

Authors:  Fu-Zhang Wang; Frank Weber; Carlo Croce; Chang-Gong Liu; Xudong Liao; Philip E Pellett
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

Review 8.  Adrenocortical cancer: pathophysiology and clinical management.

Authors:  Rossella Libè; Amato Fratticci; Jérôme Bertherat
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

9.  Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer.

Authors:  Hideki Yamada; Kiyoshi Yanagisawa; Shogo Tokumaru; Ayumu Taguchi; Yuji Nimura; Hirotaka Osada; Masato Nagino; Takashi Takahashi
Journal:  Genes Chromosomes Cancer       Date:  2008-09       Impact factor: 5.006

10.  Nephroblastoma overexpressed/cysteine-rich protein 61/connective tissue growth factor/nephroblastoma overexpressed gene-3 (NOV/CCN3), a selective adrenocortical cell proapoptotic factor, is down-regulated in childhood adrenocortical tumors.

Authors:  Mabrouka Doghman; Malika Arhatte; Hélène Thibout; Giovanna Rodrigues; Juliana De Moura; Sébastien Grosso; Alina Nico West; Maryvonne Laurent; Jean-Christophe Mas; André Bongain; Gerard P Zambetti; Bonald C Figueiredo; Patrick Auberger; Cécile Martinerie; Enzo Lalli
Journal:  J Clin Endocrinol Metab       Date:  2007-06-12       Impact factor: 5.958

View more
  94 in total

1.  Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.

Authors:  Maria Cristina De Martino; Peter M van Koetsveld; Richard A Feelders; Steven W J Lamberts; Wouter W de Herder; Annamaria Colao; Rosario Pivonello; Leo J Hofland
Journal:  Endocrine       Date:  2015-12-08       Impact factor: 3.633

Review 2.  Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

Authors:  Gaetano Santulli; Hana Totary-Jain
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 3.  The cAMP pathway and the control of adrenocortical development and growth.

Authors:  Cyrille de Joussineau; Isabelle Sahut-Barnola; Isaac Levy; Emmanouil Saloustros; Pierre Val; Constantine A Stratakis; Antoine Martinez
Journal:  Mol Cell Endocrinol       Date:  2011-10-15       Impact factor: 4.102

4.  Regulation of onco and tumor suppressor MiRNAs by mTORC1 inhibitor PRP-1 in human chondrosarcoma.

Authors:  Karina A Galoian; Toumy Guettouche; Biju Issac; Amir Qureshi; H T Temple
Journal:  Tumour Biol       Date:  2013-11-01

5.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

6.  Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma.

Authors:  Zujian Chen; Yi Jin; Dongsheng Yu; Anxun Wang; Ishrat Mahjabeen; Cheng Wang; Xiqiang Liu; Xiaofeng Zhou
Journal:  Oral Oncol       Date:  2012-03-17       Impact factor: 5.337

7.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

Review 8.  Minireview: miRomics in endocrinology: a novel approach for modeling endocrine diseases.

Authors:  Péter M Szabó; Henriett Butz; Péter Igaz; Károly Rácz; László Hunyady; Attila Patócs
Journal:  Mol Endocrinol       Date:  2013-01-24

9.  CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest.

Authors:  T Bertero; C Gastaldi; I Bourget-Ponzio; B Mari; G Meneguzzi; P Barbry; G Ponzio; R Rezzonico
Journal:  Cell Death Differ       Date:  2013-02-22       Impact factor: 15.828

10.  Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis.

Authors:  Alejandro Vazquez-Martin; Tamara Sauri-Nadal; Octavio J Menendez; Cristina Oliveras-Ferraros; Sílvia Cufí; Bruna Corominas-Faja; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.